IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus

Journal of Infection

Volumn 66, Issue 2, 2013, Pages 170-178

  Guzmán Fulgencio, María ^a   Berenguer, Juan ^b   García álvarez, Mónica ^a   Fernández Rodríguez, Amanda ^a   Jiménez Sousa, María A ^a   álvarez, Emilio ^b   Micheloud, Dariela ^b   López, Juan Carlos ^b   Miralles, Pilar ^b   Cosín, Jaime ^b   Catalán, Pilar ^b   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

AIDS; Fibrosis; Hepatitis C; Liver biopsy; SNPs; Transaminases

Indexed keywords

INTERLEUKIN 28B;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENETIC LINKAGE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERLEUKINS; LINKAGE DISEQUILIBRIUM; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84871919160     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.025     Document Type: Article

References (48)

1. Lopez-Dieguez M., Montes M.L., Pascual-Pareja J.F., Quereda C., Von Wichmann M.A., Berenguer J., et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011, 25(7):899-904.
2. Macias J., Berenguer J., Japon M.A., Giron J.A., Rivero A., Lopez-Cortes L.F., et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009, 50(4):1056-1063.
3. Lo Re V., Kostman J.R., Amorosa V.K. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008, 12(3):587-609. [ix].
4. Bhagani S. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Curr Opin HIV AIDS 2011, 6(6):483-490.
5. Moreno L., Quereda C., Moreno A., Perez-Elias M.J., Antela A., Casado J.L., et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004, 18(1):67-73.
6. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004, 18(13):F27-F36.
7. Vispo E., Barreiro P., Pineda J.A., Mira J.A., Maida I., Martin-Carbonero L., et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13(3):429-437.
8. Mira J.A., Lopez-Cortes L.F., Barreiro P., Tural C., Torres-Tortosa M., de Los Santos Gil I., et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008, 62(6):1365-1373.
9. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
10. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
11. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104.
12. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41(10):1105-1109.
13. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139(5):1577-1585. 85 e1-3.
14. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139(2):499-509.
15. Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52(6):1888-1896.
16. Spengler U., Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007, 112(3):141-155.
17. Kuntzen T., Tural C., Li B., Feldmann G., Kupfer B., Nischalke H.D., et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008, 22(2):203-210.
18. Kelly C., Klenerman P., Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011, 60(9):1284-1293.
19. Thomas E., Gonzalez V.D., Li Q., Modi A.A., Chen W., Noureddin M., et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142(4):978-988.
20. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006, 80(9):4501-4509.
21. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002, 155(7):645-653.
22. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349(9055):825-832.
23. Afdhal N.H., McHutchison J.G., Zeuzem S., Mangia A., Pawlotsky J.M., Murray J.S., et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2010, 53(1):336-345.
24. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22(15):1979-1991.
25. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130(6):1636-1642.
26. Machado M.V., Oliveira A.G., Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010, 52(1):71-78.
27. Abe H., Ochi H., Maekawa T., Hayes C.N., Tsuge M., Miki D., et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010, 53(3):439-443.
28. Bochud P.Y., Bibert S., Kutalik Z., Patin E., Guergnon J., Nalpas B., et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012, 55(2):384-394.
29. Marabita F., Aghemo A., De Nicola S., Rumi M.G., Cheroni C., Scavelli R., et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011, 54(4):1127-1134.
30. Rembeck K., Alsio A., Christensen P.B., Farkkila M., Langeland N., Buhl M.R., et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 2012, 7(1):e29370.
31. Agundez J.A., Garcia-Martin E., Maestro M.L., Cuenca F., Martinez C., Ortega L., et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 2012, 7(5):e37998.
32. Clark P.J., Thompson A.J., Zhu Q., Vock D.M., Zhu M., Patel K., et al. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 2012, 57(8):2213-2221.
33. Barreiro P., Pineda J.A., Rallon N., Naggie S., Martin-Carbonero L., Neukam K., et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011, 203(11):1629-1636.
34. Bochud P.Y., Bibert S., Negro F., Haagmans B., Soulier A., Ferrari C., et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011, 55(5):980-988.
35. Fischer J., Bohm S., Scholz M., Muller T., Witt H., George J., et al. Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection. Hepatology 2012, 55(6):1700-1710.
36. Marcellin P., Asselah T., Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36(5 Suppl. 1):S47-S56.
37. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38(1):75-85.
38. Patton H.M., Patel K., Behling C., Bylund D., Blatt L.M., Vallee M., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40(3):484-490.
39. Hui J.M., Kench J., Farrell G.C., Lin R., Samarasinghe D., Liddle C., et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002, 17(8):873-881.
40. Fartoux L., Poujol-Robert A., Guechot J., Wendum D., Poupon R., Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005, 54(7):1003-1008.
41. Ohnishi M., Tsuge M., Kohno T., Zhang Y., Abe H., Hyogo H., et al. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol 2012, 47(7):834-844.
42. Stattermayer A.F., Rutter K., Beinhardt S., Scherzer T.M., Stadlmayr A., Hofer H., et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012, 57(3):492-498.
43. Stanley T.L., Grinspoon S.K. Body composition and metabolic changes in HIV-infected patients. J Infect Dis 2012, 205(Suppl. 3):S383-S390.
44. Younossi Z.M., Afendy A., Stepanova M., Hossain N., Younossi I., Ankrah K., et al. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int 2009, 29(9):1403-1412.
45. Dill M.T., Duong F.H., Vogt J.E., Bibert S., Bochud P.Y., Terracciano L., et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140(3):1021-1031.
46. Perneger T.V. What's wrong with Bonferroni adjustments. BMJ 1998, 316(7139):1236-1238.
47. Sterne J.A., Davey Smith G. Sifting the evidence-what's wrong with significance tests?. BMJ 2001, 322(7280):226-231.
48. Burton P.R., Tobin M.D., Hopper J.L. Key concepts in genetic epidemiology. Lancet 2005, 366(9489):941-951.